Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Rick Bienkowski is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/28/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 06/24/2024 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 190.31% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/18/2024 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 190.31% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 190.31% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | LEGN | Buy Now | Legend Biotech | $44.29 | 85.14% | → $82 | Initiates | → Overweight | Get Alert |
| 11/08/2023 | CRBU | Buy Now | Caribou Biosciences | $1.64 | — | — | Initiates | → Neutral | Get Alert |
| 10/17/2023 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 36.58% | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | VERV | Buy Now | Verve Therapeutics | $4.86 | 352.67% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 09/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 190.31% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | EDIT | Buy Now | Editas Medicine | $4.69 | 198.51% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 139.01% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | VERV | Buy Now | Verve Therapeutics | $4.86 | 352.67% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/29/2023 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 190.31% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | EDIT | Buy Now | Editas Medicine | $4.69 | 198.51% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 139.01% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 190.31% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | EDIT | Buy Now | Editas Medicine | $4.69 | 219.83% | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 02/01/2023 | VERV | Buy Now | Verve Therapeutics | $4.86 | 332.1% | → $21 | Initiates | → Neutral | Get Alert |
| 02/01/2023 | EDIT | Buy Now | Editas Medicine | $4.69 | 219.83% | → $15 | Initiates | → Overweight | Get Alert |
| 02/01/2023 | NTLA | Buy Now | Intellia Therapeutics | $22.39 | 199.24% | → $67 | Initiates | → Overweight | Get Alert |
| 02/01/2023 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 164.62% | → $62 | Initiates | → Overweight | Get Alert |
| 08/10/2022 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 382.29% | $118 → $113 | Maintains | Outperform | Get Alert |
| 08/08/2022 | CRSP | Buy Now | CRISPR Therapeutics | $54.14 | 97.64% | $112 → $107 | Maintains | Outperform | Get Alert |
| 05/10/2022 | CRSP | Buy Now | CRISPR Therapeutics | $54.14 | 106.87% | $120 → $112 | Maintains | Outperform | Get Alert |
| 05/09/2022 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 416.43% | $118 → $121 | Maintains | Outperform | Get Alert |
| 02/25/2022 | EDIT | Buy Now | Editas Medicine | $4.69 | 475.69% | $41 → $27 | Maintains | Market Perform | Get Alert |
| 02/16/2022 | CRSP | Buy Now | CRISPR Therapeutics | $54.14 | 121.65% | $126 → $120 | Maintains | Outperform | Get Alert |
| 01/10/2022 | BEAM | Buy Now | Beam Therapeutics | $23.43 | 416.43% | $116 → $121 | Maintains | Outperform | Get Alert |
